Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARS1 | P26639 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31326251 | 1.00 | TARS1 (0.36) | TARS1ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL31192374 | 0.95 | ADORA2A (0.35) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL31406475 | 0.92 | ADORA2A (0.36) | TARS1ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL28304158 | 0.90 | TARS1 (0.34) | TARS1ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL27196595 | 0.89 | TARS1 (0.33) | TARS1ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL28120771 | 0.88 | TARS1 (0.35) | TARS1 | |
| SCHEMBL16987222 | 0.83 | TARS1 (0.38) | TARS1ADORA1 | |
| SCHEMBL28564130 | 0.83 | TARS1 (0.38) | TARS1ADORA1 | |
| SCHEMBL29435121 | 0.83 | TARS1 (0.38) | TARS1ADORA1 | |
| SCHEMBL29089525 | 0.82 | TARS1 (0.39) | TARS1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113396219-B | Purification of mRNA by tangential flow filtration | ETHRIS GMBH (DE) | 2026-05-26 | — | — | CN | disclosed |
| CN-120129532-A | Stabilized lipid or lipid nanoparticle suspensions | 埃泽瑞斯公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-119895037-A | System for enhancing target mRNA expression and uses thereof | 约翰霍普金斯大学 | 2025-04-25 | — | — | CN | disclosed |
| CN-113423418-B | Treatment of cilia disease | 埃泽瑞斯公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118949075-A | Treatment of cilia disease | 埃泽瑞斯公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-117729930-A | Use of IFN-lambda mRNA for the treatment of viral infections | 埃泽瑞斯公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-116887812-A | Formulations for aerosol formation and aerosols for delivery of nucleic acids | 埃泽瑞斯公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-113423418-A | Treatment of cilia disease | 埃泽瑞斯公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-113396219-A | Purification of mRNA by tangential flow filtration | 埃泽瑞斯公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-113286597-A | Precisely engineered invisible messenger RNAs and other polynucleotides | 科纳勒生物公司 | 2021-08-20 | — | — | CN | disclosed |
| CN-112004942-A | Analysis and diagnosis method using RNA modification | 国立大学法人大阪大学 | 2020-11-27 | — | — | CN | disclosed |